GYRE · NASDAQ
Gyre Therapeutics (GYRE) Stock Price & Fundamentals
Gyre Therapeutics (GYRE) closed at $582.82 on Oct 9, 2026, down 0.59% from the previous close of $586.30.
Share price, past year
1Y −4.54%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $582.82 |
| Sep 30, 2026 | $586.50 |
| Aug 31, 2026 | $576.09 |
| Jul 31, 2026 | $586.30 |
| Jun 30, 2026 | $595.19 |
| May 29, 2026 | $583.70 |
| Apr 30, 2026 | $601.03 |
| Mar 31, 2026 | $646.12 |
| Feb 27, 2026 | $623.02 |
| Jan 30, 2026 | $619.21 |
| Dec 31, 2025 | $629.47 |
| Nov 28, 2025 | $663.91 |
| Oct 31, 2025 | $638.34 |
Key statistics
- Market cap
- $61.80B
- P/E (TTM)
- —
- EPS (TTM)
- −$0.17
- Revenue (TTM)
- $116.42M
- Net income (TTM)
- −$25.67M
- Shares outstanding
- 106M
- Dividend yield
- —
- 52-week range
- $566.48 – $666.94
Gyre Therapeutics's market cap is $61.80B, based on a share price of $582.82 and 106M shares outstanding as of Jun 30, 2026.
Financials
Gyre Therapeutics reported revenue of $116.59M for fiscal 2025, up 10.24% from fiscal 2024.
Gyre Therapeutics earned net income of $9.88M in fiscal 2025, a net margin of 8.5%.
Fiscal 2025 revenue was the highest in the 10 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $116.59M | +10.2% | $9.88M | 8.5% | $0.02 | −$180.00K |
| FY2024ended Dec 31, 2024 | $105.76M | −6.8% | $17.90M | 16.9% | $0.05 | −$5.96M |
| FY2023ended Dec 31, 2023 | $113.45M | +10.9% | −$85.48M | −75.4% | −$1.41 | $17.38M |
| FY2022ended Dec 31, 2022 | $102.29M | +1,294.0% | $4.31M | 4.2% | $0.03 | $5.69M |
| FY2021ended Dec 31, 2021 | $7.34M | −65.0% | −$87.93M | −1,198.3% | −$2.87 | −$84.59M |
| FY2020ended Dec 31, 2020 | $20.95M | +349,033.3% | −$56.24M | −268.5% | −$2.93 | — |
| FY2018ended Dec 31, 2018 | $6.00K | −99.4% | −$30.06M | −500,916.7% | −$2.68 | −$28.93M |
| FY2017ended Dec 31, 2017 | $1.02M | +270.2% | −$21.56M | −2,118.0% | −$7.45 | −$19.96M |
| FY2014ended Dec 31, 2014 | $275.00K | −92.4% | — | — | — | — |
| FY2013ended Dec 31, 2013 | $3.63M | — | — | — | — | −$40.65M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $29.11M | −$14.27M | −$0.12 |
| Q1 FY2026ended Mar 31, 2026 | $22.52M | −$18.58M | −$0.10 |
| Q4 FY2025ended Dec 31, 2025 | $34.23M | $1.24M | $0.02 |
| Q3 FY2025ended Sep 30, 2025 | $30.56M | $5.94M | $0.03 |
| Q2 FY2025ended Jun 30, 2025 | $29.73M | −$2.24M | −$0.03 |
| Q1 FY2025ended Mar 31, 2025 | $22.06M | $4.94M | $0.00 |
| Q4 FY2024ended Dec 31, 2024 | $27.87M | $569.00K | $0.00 |
| Q3 FY2024ended Sep 30, 2024 | $25.49M | $2.86M | $0.01 |
Company profile
- Name
- Gyre Therapeutics, Inc.
- Ticker
- GYRE
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 12730 High Bluff Drive, Suite 250, San Diego, CA 92130
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001124105
Recent SEC filings
- Sep 1, 2026
- Aug 26, 2026
- Aug 7, 2026
- Aug 7, 2026
- Jul 16, 2026
- Jun 16, 2026
- Jun 2, 2026
- May 14, 2026
Frequently asked questions
What is Gyre Therapeutics's stock price?
Gyre Therapeutics (GYRE) closed at $582.82 on Oct 9, 2026, down 0.59% from the previous close of $586.30.
What is Gyre Therapeutics's market cap?
Gyre Therapeutics's market cap is $61.80B, based on a share price of $582.82 and 106M shares outstanding as of Jun 30, 2026.
How much revenue does Gyre Therapeutics make?
Gyre Therapeutics reported revenue of $116.59M for fiscal 2025, up 10.24% from fiscal 2024.
Does Gyre Therapeutics pay a dividend?
Gyre Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Gyre Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures